Literature DB >> 6149306

Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.

G R Breese, A A Baumeister, T J McCown, S G Emerick, G D Frye, K Crotty, R A Mueller.   

Abstract

Administration of L-dopa or apomorphine to neonatal and adult 6-hydroxydopamine (6-OHDA)-treated rats resulted in different behavioral responses depending on the age at which dopaminergic fibers were destroyed. When neonatal 6-OHDA-treated rats were tested as adults, they exhibited marked stereotypies, self-biting and self-mutilation behavior (SMB) when given these dopamine agonists. Self-biting as well as the incidence of SMB in neonatal 6-OHDA-treated rats showed dose-related changes between 10 and 100 mg/kg of L-dopa. This SMB and self-biting after L-dopa was observed as early as 22 to 24 days of age. Adult 6-OHDA-treated rats did not exhibit SMB or self-biting to L-dopa (100 mg/kg) or apomorphine (10 mg/kg), but did display paw treading and head nodding--behaviors not observed in neonatal 6-OHDA-treated rats. In addition, the locomotor response to apomorphine (1 mg/kg) was significantly greater in adult 6-OHDA-treated rats than in neonatal 6-OHDA-treated rats. Brain dopamine was reduced markedly in striatum, nucleus accumbens and olfactory tubercles in both 6-OHDA treatment groups with the reduction being slightly greater in rats treated with 6-OHDA neonatally. Serotonin content was elevated in striatum of rats treated neonatally with 6-OHDA, but not in adult 6-OHDA-treated rats. SMB and behaviors observed after L-dopa in rats treated neonatally with 6-OHDA were not apparent after L-dopa in rats with brain serotonin or norepinephrine reduced. Rats with brain dopaminergic fibers destroyed neonatally exhibited self-biting and SMB after L-dopa, suggesting that neonatal reduction of this amine is responsible for the SMB and self-biting in neonatal 6-OHDA-treated rats. 5-Hydroxytryptophan administration to neonatal 6-OHDA-treated rats did not induce SMB, indicating that release of serotonin by L-dopa is not responsible for this behavior. Because inhibition of dopamine-beta-hydroxylase did not alter the SMB response to L-dopa observed in neonatal 6-OHDA-treated rats, norepinephrine synthesized from L-dopa does not appear to contribute to the response. High doses of a decarboxylase inhibitor sufficient to inhibit conversion of dopa to dopamine in brain did not reduce the incidence of SMB. Administration of haloperidol (1 mg/kg) reduced the incidence of SMB, but did not antagonize the self-biting or the taffy pulling exhibited by L-dopa. In contrast, cisflupentixol completely blocked the SMB and self-biting induced by L-dopa.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6149306      PMCID: PMC3060042     

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  34 in total

1.  Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system.

Authors:  U Ungerstedt
Journal:  Acta Physiol Scand Suppl       Date:  1971

2.  Selective potentiation of locomotor effects of amphetamine by midbrain raphé lesions.

Authors:  D B Neill; L D Grant; S P Grossman
Journal:  Physiol Behav       Date:  1972-10

3.  Alterations in consummatory behavior following intracisternal injection of 6-hydroxydopamine.

Authors:  G R Breese; R D Smith; B R Cooper; L D Grant
Journal:  Pharmacol Biochem Behav       Date:  1973 May-Jun       Impact factor: 3.533

4.  Effect of L-dopa on the locomotor activity of rats pretreated with 6-hydroxydopamine.

Authors:  N J Uretsky; R I Schoenfeld
Journal:  Nat New Biol       Date:  1971-12-01

5.  Neurotransmitters and the Lesch-Nyhan syndrome.

Authors:  I J Kopin
Journal:  N Engl J Med       Date:  1981-11-05       Impact factor: 91.245

6.  Behavioral and prolactin responses to 5-hydroxytryptophan in rats treated during development with 5,7-dihydroxytryptamine.

Authors:  G R Breese; R A Vogel; C M Kuhn; R B Mailman; R A Mueller; S M Schanberg
Journal:  Brain Res       Date:  1978-10-27       Impact factor: 3.252

7.  Blockage of amphetamine induced motor stimulation and stereotypy in the adult rat following neonatal treatment with 6-hydroxydopamine.

Authors:  I Creese; S D Iversen
Journal:  Brain Res       Date:  1973-06-15       Impact factor: 3.252

Review 8.  Parkinson's disease: from brain homogenate to treatment.

Authors:  O Hornykiewicz
Journal:  Fed Proc       Date:  1973-02

9.  Developmental characteristics of brain catecholamines and tyrosine hydroxylase in the rat: effects of 6-hydroxydopamine.

Authors:  G R Breese; T D Traylor
Journal:  Br J Pharmacol       Date:  1972-02       Impact factor: 8.739

10.  Differential effects of para-chlorophenylalanine on amphetamine-induced locomotion and stereotypy.

Authors:  D S Segal
Journal:  Brain Res       Date:  1976-11-05       Impact factor: 3.252

View more
  42 in total

Review 1.  Stereotypic progressions in psychotic behavior.

Authors:  Richard M Kostrzewa; John P Kostrzewa; Rose Anna Kostrzewa; Florence P Kostrzewa; Ryszard Brus; Przemyslaw Nowak
Journal:  Neurotox Res       Date:  2010-04-22       Impact factor: 3.911

2.  The role of dopamine receptors in the neurobehavioral syndrome provoked by activation of L-type calcium channels in rodents.

Authors:  Suhail Kasim; Bonita L Blake; Xueliang Fan; Elena Chartoff; Kiyoshi Egami; George R Breese; Ellen J Hess; H A Jinnah
Journal:  Dev Neurosci       Date:  2006       Impact factor: 2.984

3.  Dopamine agonist-induced stereotypic grooming and self-mutilation following striatal dopamine depletion.

Authors:  S L Hartgraves; P K Randall
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  Plasticity within striatal direct pathway neurons after neonatal dopamine depletion is mediated through a novel functional coupling of serotonin 5-HT2 receptors to the ERK 1/2 map kinase pathway.

Authors:  Pierre Brown; Charles R Gerfen
Journal:  J Comp Neurol       Date:  2006-09-20       Impact factor: 3.215

5.  SCH-23390 antagonism of a D-2 dopamine agonist depends upon catecholaminergic neurons.

Authors:  G R Breese; R A Mueller
Journal:  Eur J Pharmacol       Date:  1985-07-11       Impact factor: 4.432

Review 6.  Dopamine receptor supersensitivity: development, mechanisms, presentation, and clinical applicability.

Authors:  Richard M Kostrzewa; John P Kostrzewa; Russell W Brown; Przemyslaw Nowak; Ryszard Brus
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

7.  Dopamine receptor supersensitivity: an outcome and index of neurotoxicity.

Authors:  Richard M Kostrzewa; John P Kostrzewa; Ryszard Brus
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

8.  Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo.

Authors:  D F Wong; J C Harris; S Naidu; F Yokoi; S Marenco; R F Dannals; H T Ravert; M Yaster; A Evans; O Rousset; R N Bryan; A Gjedde; M J Kuhar; G R Breese
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

9.  Dopamine receptor agonists regulate levels of the serotonin 5-HT2A receptor and its mRNA in a subpopulation of rat striatal neurons.

Authors:  N Laprade; F Radja; T A Reader; J J Soghomonian
Journal:  J Neurosci       Date:  1996-06-01       Impact factor: 6.167

10.  Effects of acute dopamine depletion on responsiveness to D1 and D2 receptor agonists in infant and weanling rat pups.

Authors:  C A Moody; L P Spear
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.